"10.1371_journal.pone.0072708","plos one","2013-08-16T00:00:00Z","Lorenzo Tibaldi; Shirley Leyman; André Nicolas; Sofie Notebaert; Melissa Dewulf; Thu Hoa Ngo; Claudia Zuany-Amorim; Nathalie Amzallag; Isabelle Bernard-Pierrot; Xavier Sastre-Garau; Clotilde Théry","Institut Curie, Centre de Recherche, Paris, France; INSERM U932, Paris, France; ThromboGenics, NV, Heverlee, Belgium; Institut Curie, Hospital, Department of Tumor Biology, Paris, France; CNRS UMR144, Paris, France; CBT-507 IGR-Curie, Paris, France","Conceived and designed the experiments: LT CT NA SL SN THN CZA. Performed the experiments: LT AN MD SN SL THN. Analyzed the data: LT AN XSG IBP NA CT SL SN THN CZA. Contributed reagents/materials/analysis tools: AN IBP XSG CT SL SN THN CZA. Wrote the manuscript: LT CT.","The authors have read the journal's policy and have the following conflicts: part of this work was subsidised by funding to Clotilde Théry's team including Lorenzo Tibaldi's salary, as a collaboration contract between Institut Curie, INSERM, and ThromboGenics NV, Belgium. Shirley Leyman, Sofie Notebaert, Thu Hoa Ngo and Claudia Zuany-Amorim are employed by ThromboGenics NV. An international PCT application covering the described antibodies, co-owned by ThromboGenics NV, Institut Curie and INSERM, has been filed under the number PCT/EP2013/056057. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials with academic laboratories.","2013","08","Lorenzo Tibaldi","LT",11,TRUE,7,6,10,2,TRUE,TRUE,FALSE,0,NA,FALSE
